In this episode of ATTD 2025 Conference Catch-Up, we dive into View, Counterview: Time in Tight Range Should Be the Primary Treatment Goals and Outcome Measure in Diabetes, featuring a lively debate on the role of time in tight range as a primary treatment goal, weighing the benefits of advanced CGM technology against the potential psychological and practical challenges.Join us as we summarize key takeaways from these thought-provoking presentations:View – Dr. Anders CarlsonCounterview – Dr. Jeremy Pettus Rebuttal by Speaker Presenting View – Dr. Anders CarlsonRebuttal by Speaker Presenting Counterview – Dr. Jeremy PettusThis episode is an essential listen for endocrinologists, diabetes specialists, and healthcare professionals looking to explore the role of tight glycemic control in diabetes management, understand the advantages and challenges of using time in range as an outcome measure, and gain insight into the evolving landscape of diabetes care.Enjoy the listen!This podcast was created using AI to provide a quick and insightful summary of an ATTD 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.ATTD 2025, the 18th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on March 19-22, 2025, in Amsterdam.https://attd.kenes.com

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related